ReviewPaediatric respiratory reviews2018
Childhood community-acquired pneumonia: A review of etiology- and antimicrobial treatment studies.
Review in Paediatric respiratory reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- Procalcitonin and lung ultrasound algorithm to diagnose severe pneumonia in critical paediatric patients (PROLUSP study). A randomised clinical trial.Respiratory research · 2020Trial
- Trial
- Treatment practices and outcomes of chest indrawing pneumonia in children aged 2-59 months in primary health facilities of Kamuli District, Eastern Uganda.Journal of global health · 2026Observational
- Comparison of the effectiveness of penicillin and broad-spectrum β-lactam antibiotics in the treatment of community-acquired pneumonia in children.Archives of medical science : AMS · 2026Article
- Use of the Proportion of Neutrophils in Bronchoalveolar Lavage Fluid for Rapid Diagnosis of Bacterial Pneumonia in Children.Infection and drug resistance · 2026Article
- Characteristics and risk factors for outcomes in patients withInfectious Disease Modelling · 2025Article
- Monitoring human adenovirus loads in bronchoalveolar lavage fluid in non-immunocompromised children with human adenovirus pneumonia.Translational pediatrics · 2025Article
- Current Trends in Antibiotic Therapy and Resistance: A Comparative Study of Various Spectrums.Cureus · 2025Article
- Microbiological aetiology of paediatric respiratory tract infections in Kyrgyzstan.BMC infectious diseases · 2025Article
- Shorter treatments for (febrile) urinary tract infections: are we there?Translational pediatrics · 2025Article
- Lung ultrasound for the diagnosis and monitoring of community-acquired pneumonia in children: a prospective observational study.Frontiers in pediatrics · 2025Article
- Is There a Pediatric Role for the General Thoracic Surgeon in a General Hospital? A 22-Year Single-Center Experience.Journal of clinical medicine · 2024Article
- Evaluation and clinical significance of serum neurospecific enolase in children with pneumonia: a case-control study.BMC pediatrics · 2024Article
- Dynamics of platelet parameters in children with severe community-acquired pneumonia between viral and bacterial infections.Translational pediatrics · 2024Article
- Viral and bacterial microorganisms in Vietnamese children with severe and non-severe pneumonia.Scientific reports · 2024Article
- Associations of MMP9 polymorphism with the risk of severe pneumonia in a Southern Chinese children population.BMC infectious diseases · 2024Article
- Antibiotic resistance ofFrontiers in public health · 2023Article
- Applications of mPCR testing reduced initial antibiotic use and duration of mechanical ventilation in virus-infected children with severe community-acquired pneumonia admitted to the PICU.World journal of pediatrics : WJP · 2022Article
- Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial.Frontiers in pharmacology · 2022Article
- Intestinal Flora: A Potential Mechanism by WhichEvidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community acquired pneumonia (CAP) is a leading cause of childhood morbidity worldwide. Because of the rising antimicrobial resistance rates and adverse effects of childhood antibiotic use on the developing microbiome, rational prescribing of antibiotics for CAP is important. This review summarizes and critically reflects on the available evidence for the epidemiology, etiology and antimicrobial management of childhood CAP. Larger prospective studies on antimicrobial management derive mostly from low- or middle-income countries as they have the highest burden of CAP. Optimal antimicrobial management depends on the etiology, age, local vaccination policies and resistance patterns. As long as non-rapid surrogate markers are used to distinguish viral- from bacterial pneumonia, the management is probably suboptimal. For a young child with signs of non-severe pneumonia (with or without wheezing), watchful waiting is recommended because of probable viral etiology. For children with more severe CAP with fever, a five-day oral amoxicillin course would be the first choice therapy and dosage will depend on local resistance rates. There is no clear evidence yet for superiority of a macrolide-based regimen for all ages. For cases with CAP requiring hospitalization, several studies have shown that narrow-spectrum IV beta-lactam therapy is as effective as a broad-spectrum cephalosporin therapy. For most severe disease, broad-spectrum therapy with or without a macrolide is suggested. In case of empyema, rapid IV-to-oral switch seems to be equivalent to prolonged IV treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.